quality and affordable protein therapeutics
Kun-Liang Guan, a biochemist and cell biologist, is a chair professor at Westlake University. He received his BS (1982) from Hangzhou University and PhD (1989) from Purdue University. Dr. Guan was a faculty at the University of Michigan between 1992-2007 and at the University of California San Diego between 2007-2023. He was awarded the MacArthur Fellowship (1998), the American Society of Biochemistry and Molecular Biology Young Investigator Award (1999), and AAAS Fellow (2011). His research focuses on cellular signaling in cell growth, organ size control, and cancer. Dr. Guan’s group has made key contributions to mTOR and Hippo signaling pathways. He is the most and second most cited investigator in Hippo and mTOR, respectively. Dr. Guan has published over 300 peer-reviewed papers and is one of the most highly cited researchers in Molecular Biology and Genetics.
Professor Yang-Xin Fu is an endowed Professor at Tsinghua University. He received his Ph.D. in Microbiology and Immunology form University of Miami (1990). He was endowed professor and attending physician in the University of Chicago from 1998 to 2015 and then UT southwestern medical center.
Professor Lixin Zhang is the Director of National Key Laboratory of Bioreactor Engineering at East China University of Science and Technology. His research focused on taxonomy-guided diversification of marine microbial natural product library: mining synergistic medicines through high throughput screening and increasing their production titers through synthetic biology strategy. His Avermectin project received The National Award for Excellence in Science and Technologies. In addition, he was an Awardee of the National Science Fund for Distinguished Young Scholars, and was awarded the Chief Scientist of a “973 Program”,“Roche Young Investigator Award” etc.. His academic achievements and technological innovations are highlighted by 7 books, over 300 papers published in Nature Biotechnology and other international journals and 44 patents (28 Chinese patents and 16 PCT patents).
K. Christopher Garcia, Ph.D is a Professor of Molecular and Cellular Physiology, and of Structural Biology at the Stanford University School of Medicine. He received his B.S. in Biochemistry from Tulane University, and his Ph.D in Biophysics from Johns Hopkins University. Dr. Garcia was elected to the National Academy of Sciences in 2012, and the National Academy of Medicine in 2016.
Alberto Mantovani, MD, is Emeritus Professor of Pathology at the Humanitas University in Milan, Scientific Director of the Istituto Clinico Humanitas and Chair of Inflammation and Therapeutic Innovation, William Harvey Research Institute, Queen Mary University, London, UK. His attention has been focused on molecular mechanisms of innate immunity and inflammation and on the role in the tumor microenvironment and cancer progression of tumor-associated macrophages (TAM). He has contributed to the advancement of knowledge in the field of Immunology formulating new paradigms and identifying new molecules and functions.
For his research activity he has received several national and international awards, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award for his contribution to tumor immunology and immunotherapy, the American-Italian Cancer Foundation (AICF) Prize for Excellence in Medicine, the American Association for Cancer Research International Pezcoller Award for Extraordinary Achievement in Cancer Research and, most recently, the CIMT Lifetime Achievement Award. The broad impact of his contributions is testified by citations. As of June 2023 he has over 161,000 citations and an H-index of 184 (Scopus).
Dr. Abbas received his medical degree (MBBS) in India, completed training in Pathology at Harvard and joined the faculty at Harvard Medical School and the Brigham and Women’s Hospital, where he rose to become Professor of Pathology and Head of the Immunology Research Division. From 1999-2018, he was Professor and Chairman of the Department of Pathology at the University of California San Francisco. He has received several honors, including election to the National Academy of Medicine, election as a Fellow of the American Academy of Arts and Sciences, and the Rous-Whipple, Robbins Educator and Gold-Headed Cane Awards of the American Society of Investigative Pathology. He has served as one of the inaugural Editors and Associate Editor of Immunity, Associate Editor and Section Editor for The Journal of Immunology, Associate Editor of Cell, Consulting Editor of The Journal of Clinical Investigation, and founding Editor of the Annual Review of Pathology: Mechanisms of Disease. From 2011-2013, he was the President of the Federation of Clinical Immunology Societies (FOCIS).
Dr. Abbas’ research interests are in Immunology, with a focus on the control of immune responses and the causes of autoimmunity. His laboratory used experimental models to analyze the generation and maintenance of regulatory T cells. He has published over 200 peer-reviewed papers and invited reviews, and is the author of four widely read textbooks, two in Immunology and two in Pathology. He has taught Immunology at Harvard Medical School and UCSF, and has organized and conducted Immunology courses worldwide.
David Gandara, Professor of Medicine Emeritus at the University of California, Davis. He is the co-director of the Center for Experimental Therapeutics in Cancer and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center. He was recently appointed Adjunct Clinical Professor, Translational and Clinical Research Program at the University of Hawaii Cancer Center and Chief Medical Officer for International Society of Liquid Biopsy (ISLB) a non-profit organization dedicated to advancing the science and clinical application of liquid biopsy in cancer diagnosis and therapy. He is an internationally known clinician-scientist and lung cancer thought leader, and has published over 450 peer-reviewed papers. Dr. Gandara has been selected for many awards and honors including the lifetime Scientific Award from the International Association for Study of Lung Cancer (IASLC), the Team Science Award from the Addario Lung Cancer Foundation, and the Trajectory Achievement Award from the ISLB. He is current principal investigator for a National Cancer Institute UG1 award to UCDCCC for cancer clinical trials, co-leader of Lung MAP, a unique NCI-sponsored public-private partnership for new drug development in lung cancer, and is founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). Dr. Gandara is past Editor-in-Chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of ASCO. In 2017, Gandara received the Giants of Cancer Care Award in lung cancer.